bioMerieux (OTCMKTS:BMXMF) Stock Passes Above Fifty Day Moving Average – Time to Sell?

Posted by Scott Moore on Sep 6th, 2026

bioMerieux (OTCMKTS:BMXMF – Get Free Report)’s share price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $81.55 and traded as high as $86.1070. bioMerieux shares last traded at $86.1070, with a volume of 46 shares.

Wall Street Analyst Weigh In

BMXMF has been the topic of several recent analyst reports. UBS Group downgraded shares of bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Zacks Research cut shares of bioMerieux from a “hold” rating to a “strong sell” rating in a research report on Friday, July 31st. Morgan Stanley downgraded shares of bioMerieux from an “overweight” rating to an “underweight” rating in a report on Tuesday, June 23rd. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th. Finally, Piper Sandler began coverage on shares of bioMerieux in a research note on Thursday, June 11th. They set a “neutral” rating on the stock. Four investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

Check Out Our Latest Report on bioMerieux

bioMerieux Trading Down 0.9%

The business has a 50 day simple moving average of $81.55 and a 200 day simple moving average of $91.74. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.39 and a quick ratio of 1.48.

bioMerieux Company Profile

(Get Free Report)

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.